Baxalta's blueprint

Now that Baxalta Inc. has completed its spinout from Baxter International Inc., the newco's ambitious plan is to launch 20 new drugs, including line extensions, by 2020. The products, which come from a mix of recent BD activity and homegrown programs, will employ a revamped R&D strategy that taps patients for input early in development to ensure the end product meets their needs.

Baxter announced plans to spin out its drug pipeline and products into a separate company in March 2014, and the separation became official on July 1 with Baxalta's debut on the New York Stock Exchange. The parent kept its medical product business, while Baxalta emerged from the biopharmaceutical business which was housed in the Baxter BioScience unit. ...